The Paris Private Equity team advised UroMems in its €16 million fundraising to advance the development of Electronic Artificial Urinary Sphincter (eAUS) for stress urinary incontinence.
Based in Grenoble, UroMems is a French innovative medtech company designing, developing and commercializing active implantable medical device..
This financing was completed with the participation of existing investors (Wellington Partners, Bpifrance, Cita Investissement, Supernova Invest and b-to-v Partners AG) as well as new investors, Hil-Invent Gmbh and Financière Arbevel. The capital will be used to fund clinical trials.
The Goodwin team was led by partner, Thomas Dupont-Sentilles.